LASSBio-1135: a dual TRPV1 antagonist and anti-TNF-alpha compound orally effective in models of inflammatory and neuropathic pain.

LASSBio-1135: a dual TRPV1 antagonist and anti-TNF-alpha compound orally effective in models of inflammatory and neuropathic pain.

LASSBio-1135 is an imidazo[1,2-a]pyridine derivative with high efficacy in screening models of nociception and inflammation, presumed as a weak COX-2 inhibitor. In order to tease out its mechanism of action, we investigated others possible target for LASSBio-1135, such as TNF-α and TRPV1, to better...

Full description

Saved in:
Bibliographic Details
Main Authors: Cleverton K F Lima, Rafael M Silva, Renata B Lacerda, Bruna L R Santos, Rafaela V Silva, Luciana S Amaral, Luís E M Quintas, Carlos A M Fraga, Eliezer J Barreiro, Marília Z P Guimaraes, Ana L P Miranda
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2014
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/b97ee205c4954b879b42ed0c9e63345c
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items